TIAM2
BCLI

Tru Independence Asset Management 2’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Tru Independence Asset Management 2’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,933
Closed -$10.1K – 81
2024
Q3 		$10.1K Buy
+2,933
New +$13.8K 0.01% 82
2023
Q1 		$145K Buy
+2,933
New +$85.1K 0.15% 73
2022
Q3 		$194K Buy
+2,933
New +$147K 0.21% 67

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tru Independence Asset Management 2's BCLI Position: Q4 2024 in Review

Tru Independence Asset Management 2 sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 2,933 shares — an estimated $10.1K sold.

Tru Independence Asset Management 2 first reported a position in BCLI in Q3 2022 and held it in 3 quarters. The position peaked at $194K in Q3 2022. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Tru Independence Asset Management 2 reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Tru Independence Asset Management 2 sold 2,933 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $10.1K.
  • Tru Independence Asset Management 2 first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2022 and held it in 3 quarters.
  • Tru Independence Asset Management 2's BRAINSTORM CELL THERAPUTC position peaked at $194K in Q3 2022.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Tru Independence Asset Management 2's 13F filing for Q4 2024, filed 22 Jan 2025.